DOCSLIB.ORG

Epitect® Chip Qpcr Array Mouse Cancer Drug Targets

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Epitect® Chip Qpcr Array Mouse Cancer Drug Targets EpiTect® ChIP qPCR Array Mouse Cancer Drug Targets Cat. NO. 334211 GM-507A For chromatin immunoprecipitation analysis Format For use with the following real-time cyclers EpiTect ChIP qPCR Array Applied Biosystems® models 5700, 7000, 7300, 7500, Format A 7700, 7900HT, ViiA™ 7 (96-well block); Bio-Rad® models iCycler®, iQ™5, MyiQ™, MyiQ2; Bio-Rad/MJ Research Chromo4™; Eppendorf® MasterCycler® ep realplex models 2, 2s, 4, 4s; Stratagene® models Mx3005P®, Mx3000P®; Takara: TP-800 EpiTect ChIP qPCR Array Applied Biosystems models 7500 (Fast block), 7900HT (Fast Format C block), StepOnePlus™, ViiA 7 (Fast block) EpiTect ChIP qPCR Array Bio-Rad CFX96™; Bio-Rad/MJ Research models DNA Format D Engine Opticon®, DNA Engine Opticon 2; Stratagene Mx4000® EpiTect ChIP qPCR Array Applied Biosystems models 7900HT (384-well block), ViiA 7 Format E (384-well block); Bio-Rad CFX384™ EpiTect ChIP qPCR Array Roche® LightCycler® 480 (96-well block) Format F EpiTect ChIP qPCR Array Roche: LightCycler 480 (384-well block) Format G Sample & Assay Technologies Description The Mouse Cancer Drug Targets EpiTect ChIP qPCR Array profiles the histone modification status or “histone code” of 84 actively sought targets for anticancer therapeutics and drug development. Histone modifications define chromatin structure, and some correlate closely with the transcriptional activity of associated genes. In vitro screening of therapeutics for a given cancer type increasingly depends on not only the activity, but also the expression and epigenetic status of oncogenes. For example, histone deacetylase (HDAC) inhibitors induce tumor suppressor gene expression, slowing growth and proliferation, but could also increase oncogene expression. The choice to add HDAC inhibitors to a drug regimen can depend on the histone codes of the two gene classes. Cancer cells with oncogenes in a heterochromatin state may respond better to HDAC inhibitor treatment because these genes would not be expressed or easily induced. Comprehensively understanding how oncogenes contribute to tumor growth and survival on the molecular level requires a determination of the epigenetic mechanisms regulating their expression. Using chromatin immunoprecipitation and this qPCR Array, you can easily and reliably analyze the histone modification patterns associated with a focused panel of important cancer-related genes. For further details, consult the EpiTect ChIP qPCR Array Handbook. Shipping and storage EpiTect ChIP qPCR Arrays are shipped at room temperature (15–25ºC), on dry ice, or on blue ice depending on the destination and accompanying products. They should be stored at –20°C. Ensure that you have the correct EpiTect ChIP qPCR Array format for your instrument before starting the experiment. Note: Open the package and store the products appropriately immediately on receipt. Array layout 1 2 3 4 5 6 7 8 9 10 11 12 A Abcc1 Akt1 Akt2 Atf2 Aurka Aurkb Aurkc Bcl2 Birc5 Cdc25a Cdc2a Cdk2 B Cdk4 Cdk5 Cdk7 Cdk8 Cdk9 Ctsb Ctsd Ctsl Ctss Egfr Erbb2 Erbb3 C Erbb4 Esr1 Esr2 Figf Flt1 Flt4 Frap1 Grb2 Gstp1 Hdac1 Hdac11 Hdac2 D Hdac3 Hdac4 Hdac6 Hdac7a Hdac8 Hif1a Hras1 Hsp90aa1 Hsp90b1 Igf1 Igf1r Igf2 E Irf5 Kdr Kit Kras Mdm2 Mdm4 Nfkb1 Nras Ntn2l Parp1 Parp2 Parp4 F Pdgfra Pdgfrb Pgr Pik3c2a Pik3c3 Pik3ca Plk1 Plk2 Plk3 Plk4 Prkca Prkcb1 G Prkcd Prkce Ptgs2 Rhoa Rhob Tert Tnks Top2a Top2b Trp53 Txn1 Txnrd1 H Gapdh Gapdh Gapdh Actb Rpl30 Myod1 Serpina1a IAP Minor_sat IGX1A PPC PPC Gene table Gene Position UniGene GenBank Description Primer Catalog No. Symbol ATP-binding cassette, sub-family C (CFTR/MRP), A01 Mm.196634 NM_008576 Abcc1 GPM1032369(+)01A member 1 A02 Mm.6645 NM_009652 Akt1 Thymoma viral proto-oncogene 1 GPM1044734(+)01A A03 Mm.177194 NM_007434 Akt2 Thymoma viral proto-oncogene 2 GPM1038783(+)01A A04 Mm.209903 NM_009715 Atf2 Activating transcription factor 2 GPM1048723(+)01A A05 Mm.249363 NM_011497 Aurka Aurora kinase A GPM1049426(+)01A A06 Mm.3488 NM_011496 Aurkb Aurora kinase B GPM1029562(+)01A A07 Mm.261572 NM_020572 Aurkc Aurora kinase C GPM1038476(+)01A A08 Mm.257460 NM_009741 Bcl2 B-cell leukemia/lymphoma 2 GPM1042316(+)01A A09 Mm.8552 NM_009689 Birc5 Baculoviral IAP repeat-containing 5 GPM1030084(+)01A A10 Mm.307103 NM_007658 Cdc25a Cell division cycle 25 homolog A (S. pombe) GPM1041032(+)01A A11 Cdc2a GPM1042918(+)01A A12 Mm.111326 NM_016756 Cdk2 Cyclin-dependent kinase 2 GPM1043270(+)01A B01 Mm.6839 NM_009870 Cdk4 Cyclin-dependent kinase 4 GPM1029124(+)01A B02 Mm.298798 NM_007668 Cdk5 Cyclin-dependent kinase 5 GPM1051112(+)01A B03 Mm.259718 NM_009874 Cdk7 Cyclin-dependent kinase 7 GPM1045273(+)01A B04 Mm.260576 NM_153599 Cdk8 Cyclin-dependent kinase 8 GPM1037655(+)01A B05 Mm.27557 NM_130860 Cdk9 Cyclin-dependent kinase 9 (CDC2-related kinase) GPM1048574(+)01A B06 Mm.236553 NM_007798 Ctsb Cathepsin B GPM1031687(+)01A B07 Mm.231395 NM_009983 Ctsd Cathepsin D GPM1053898(+)01A B08 Mm.930 NM_009984 Ctsl Cathepsin L GPM1045101(+)01A B09 Mm.3619 NM_021281 Ctss Cathepsin S GPM1035741(+)01A B10 Mm.8534 NM_007912 Egfr Epidermal growth factor receptor GPM1029266(+)01A V-erb-b2 erythroblastic leukemia viral oncogene NM_00100381 B11 Mm.290822 Erbb2 homolog 2, neuro/glioblastoma derived oncogene GPM1029886(+)01A 7 homolog (avian) V-erb-b2 erythroblastic leukemia viral oncogene B12 Mm.373043 NM_010153 Erbb3 GPM1043263(+)01A homolog 3 (avian) V-erb-a erythroblastic leukemia viral oncogene C01 Mm.442420 NM_010154 Erbb4 GPM1042163(+)01A homolog 4 (avian) C02 Mm.9213 NM_007956 Esr1 Estrogen receptor 1 (alpha) GPM1042706(+)01A C03 Mm.2561 NM_010157 Esr2 Estrogen receptor 2 (beta) GPM1044534(+)01A C04 Mm.297978 NM_010216 Figf C-fos induced growth factor GPM1041892(+)01A C05 Mm.389712 NM_010228 Flt1 FMS-like tyrosine kinase 1 GPM1051798(+)01A C06 Mm.3291 NM_008029 Flt4 FMS-like tyrosine kinase 4 GPM1029390(+)01A C07 Frap1 GPM1036777(+)01A C08 Mm.439649 NM_008163 Grb2 Growth factor receptor bound protein 2 GPM1044218(+)01A C09 Mm.299292 NM_013541 Gstp1 Glutathione S-transferase, pi 1 GPM1047950(+)01A C10 Mm.202504 NM_008228 Hdac1 Histone deacetylase 1 GPM1050764(+)01A C11 Mm.206218 NM_144919 Hdac11 Histone deacetylase 11 GPM1038125(+)01A C12 Mm.19806 NM_008229 Hdac2 Histone deacetylase 2 GPM1028648(+)01A D01 Mm.20521 NM_010411 Hdac3 Histone deacetylase 3 GPM1047760(+)01A D02 Mm.318567 NM_207225 Hdac4 Histone deacetylase 4 GPM1042284(+)01A D03 Mm.29854 NM_010413 Hdac6 Histone deacetylase 6 GPM1055271(+)01A D04 Hdac7a GPM1046414(+)01A D05 Mm.328128 NM_027382 Hdac8 Histone deacetylase 8 GPM1055710(+)01A D06 Mm.3879 NM_010431 Hif1a Hypoxia inducible factor 1, alpha subunit GPM1030367(+)01A D07 Mm.334313 NM_008284 Hras1 Harvey rat sarcoma virus oncogene 1 GPM1053866(+)01A Heat shock protein 90, alpha (cytosolic), class A D08 Mm.1843 NM_010480 Hsp90aa1 GPM1044715(+)01A member 1 Gene Position UniGene GenBank Description Primer Catalog No. Symbol D09 Mm.87773 NM_011631 Hsp90b1 Heat shock protein 90, beta (Grp94), member 1 GPM1043076(+)01A D10 Mm.268521 NM_010512 Igf1 Insulin-like growth factor 1 GPM1028975(+)01A D11 Mm.275742 NM_010513 Igf1r Insulin-like growth factor I receptor GPM1039101(+)01A D12 Mm.3862 NM_010514 Igf2 Insulin-like growth factor 2 GPM1053902(+)01A E01 Mm.6479 NM_012057 Irf5 Interferon regulatory factor 5 GPM1037769(+)01A E02 Mm.285 NM_010612 Kdr Kinase insert domain protein receptor GPM1051307(+)01A E03 Mm.247073 NM_021099 Kit Kit oncogene GPM1037166(+)01A E04 Mm.383182 NM_021284 Kras V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog GPM1052533(+)01A E05 Mm.22670 NM_010786 Mdm2 Transformed mouse 3T3 cell double minute 2 GPM1043184(+)01A E06 Mm.426531 NM_008575 Mdm4 Transformed mouse 3T3 cell double minute 4 GPM1042387(+)01A Nuclear factor of kappa light polypeptide gene E07 Mm.256765 NM_008689 Nfkb1 GPM1050113(+)01A enhancer in B-cells 1, p105 E08 Mm.400954 NM_010937 Nras Neuroblastoma ras oncogene GPM1035803(+)01A E09 Ntn2l GPM1047125(+)01A E10 Mm.277779 NM_007415 Parp1 Poly (ADP-ribose) polymerase family, member 1 GPM1028483(+)01A E11 Mm.281482 NM_009632 Parp2 Poly (ADP-ribose) polymerase family, member 2 GPM1031514(+)01A NM_00114597 E12 Mm.213013 Parp4 Poly (ADP-ribose) polymerase family, member 4 GPM1031649(+)01A 8 Platelet derived growth factor receptor, alpha F01 Mm.221403 NM_011058 Pdgfra GPM1037164(+)01A polypeptide F02 Mm.4146 NM_008809 Pdgfrb Platelet derived growth factor receptor, beta polypeptide GPM1033712(+)01A F03 Mm.12798 NM_008829 Pgr Progesterone receptor GPM1040396(+)01A Phosphatidylinositol 3-kinase, C2 domain containing, F04 Mm.3810 NM_011083 Pik3c2a GPM1053676(+)01A alpha polypeptide F05 Mm.194127 NM_181414 Pik3c3 Phosphoinositide-3-kinase, class 3 GPM1033503(+)01A Phosphatidylinositol 3-kinase, catalytic, alpha F06 Mm.260521 NM_008839 Pik3ca GPM1035429(+)01A polypeptide F07 Mm.16525 NM_011121 Plk1 Polo-like kinase 1 (Drosophila) GPM1039450(+)01A F08 Mm.380 NM_152804 Plk2 Polo-like kinase 2 (Drosophila) GPM1031130(+)01A F09 Mm.259022 NM_013807 Plk3 Polo-like kinase 3 (Drosophila) GPM1050650(+)01A F10 Mm.3794 NM_011495 Plk4 Polo-like kinase 4 (Drosophila) GPM1035463(+)01A F11 Mm.222178 NM_011101 Prkca Protein kinase C, alpha GPM1044164(+)01A F12 Prkcb1 GPM1039452(+)01A G01 Mm.2314 NM_011103 Prkcd Protein kinase C, delta GPM1045530(+)01A G02 Mm.24614 NM_011104 Prkce Protein kinase C, epsilon GPM1033382(+)01A G03 Mm.292547 NM_011198 Ptgs2 Prostaglandin-endoperoxide synthase 2 GPM1028298(+)01A G04 Mm.757 NM_016802 Rhoa Ras homolog gene family, member A GPM1041002(+)01A G05 Mm.687 NM_007483 Rhob Ras homolog gene family, member B GPM1044334(+)01A G06 Mm.10109 NM_009354 Tert
Load more

Recommended publications
  • Gene Symbol Gene Description ACVR1B Activin a Receptor, Type IB
    Table S1. Kinase clones included in human kinase cDNA library for yeast two-hybrid screening Gene Symbol Gene Description ACVR1B activin A receptor, type IB ADCK2 aarF domain containing kinase 2 ADCK4 aarF domain containing kinase 4 AGK multiple substrate lipid kinase;MULK AK1 adenylate kinase 1 AK3 adenylate kinase 3 like 1 AK3L1 adenylate kinase 3 ALDH18A1 aldehyde dehydrogenase 18 family, member A1;ALDH18A1 ALK anaplastic lymphoma kinase (Ki-1) ALPK1 alpha-kinase 1 ALPK2 alpha-kinase 2 AMHR2 anti-Mullerian hormone receptor, type II ARAF v-raf murine sarcoma 3611 viral oncogene homolog 1 ARSG arylsulfatase G;ARSG AURKB aurora kinase B AURKC aurora kinase C BCKDK branched chain alpha-ketoacid dehydrogenase kinase BMPR1A bone morphogenetic protein receptor, type IA BMPR2 bone morphogenetic protein receptor, type II (serine/threonine kinase) BRAF v-raf murine sarcoma viral oncogene homolog B1 BRD3 bromodomain containing 3 BRD4 bromodomain containing 4 BTK Bruton agammaglobulinemia tyrosine kinase BUB1 BUB1 budding uninhibited by benzimidazoles 1 homolog (yeast) BUB1B BUB1 budding uninhibited by benzimidazoles 1 homolog beta (yeast) C9orf98 chromosome 9 open reading frame 98;C9orf98 CABC1 chaperone, ABC1 activity of bc1 complex like (S. pombe) CALM1 calmodulin 1 (phosphorylase kinase, delta) CALM2 calmodulin 2 (phosphorylase kinase, delta) CALM3 calmodulin 3 (phosphorylase kinase, delta) CAMK1 calcium/calmodulin-dependent protein kinase I CAMK2A calcium/calmodulin-dependent protein kinase (CaM kinase) II alpha CAMK2B calcium/calmodulin-dependent
    [Show full text]
  • Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association Between BMI and Adult-Onset Non- Atopic
    Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association between BMI and Adult-Onset Non- Atopic Asthma Ayoung Jeong 1,2, Medea Imboden 1,2, Akram Ghantous 3, Alexei Novoloaca 3, Anne-Elie Carsin 4,5,6, Manolis Kogevinas 4,5,6, Christian Schindler 1,2, Gianfranco Lovison 7, Zdenko Herceg 3, Cyrille Cuenin 3, Roel Vermeulen 8, Deborah Jarvis 9, André F. S. Amaral 9, Florian Kronenberg 10, Paolo Vineis 11,12 and Nicole Probst-Hensch 1,2,* 1 Swiss Tropical and Public Health Institute, 4051 Basel, Switzerland; [email protected] (A.J.); [email protected] (M.I.); [email protected] (C.S.) 2 Department of Public Health, University of Basel, 4001 Basel, Switzerland 3 International Agency for Research on Cancer, 69372 Lyon, France; [email protected] (A.G.); [email protected] (A.N.); [email protected] (Z.H.); [email protected] (C.C.) 4 ISGlobal, Barcelona Institute for Global Health, 08003 Barcelona, Spain; [email protected] (A.-E.C.); [email protected] (M.K.) 5 Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain 6 CIBER Epidemiología y Salud Pública (CIBERESP), 08005 Barcelona, Spain 7 Department of Economics, Business and Statistics, University of Palermo, 90128 Palermo, Italy; [email protected] 8 Environmental Epidemiology Division, Utrecht University, Institute for Risk Assessment Sciences, 3584CM Utrecht, Netherlands; [email protected] 9 Population Health and Occupational Disease, National Heart and Lung Institute, Imperial College, SW3 6LR London, UK; [email protected] (D.J.); [email protected] (A.F.S.A.) 10 Division of Genetic Epidemiology, Medical University of Innsbruck, 6020 Innsbruck, Austria; [email protected] 11 MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, W2 1PG London, UK; [email protected] 12 Italian Institute for Genomic Medicine (IIGM), 10126 Turin, Italy * Correspondence: [email protected]; Tel.: +41-61-284-8378 Int.
    [Show full text]
  • Involvement of the PRKCB1 Gene in Autistic Disorder
    Molecular Psychiatry (2009) 14, 705–718 & 2009 Nature Publishing Group All rights reserved 1359-4184/09 $32.00 www.nature.com/mp ORIGINAL ARTICLE Involvement of the PRKCB1 gene in autistic disorder: significant genetic association and reduced neocortical gene expression C Lintas1,2,14, R Sacco1,2,14, K Garbett3, K Mirnics3,4, R Militerni5, C Bravaccio6, P Curatolo7, B Manzi7, C Schneider8, R Melmed9, M Elia10, T Pascucci11,12, S Puglisi-Allegra11,12, K-L Reichelt13 and AM Persico1,2 1Laboratory of Molecular Psychiatry and Neurogenetics, University ‘Campus Bio-Medico’, Rome, Italy; 2Laboratory of Molecular Psychiatry and Psychiatric Genetics, Department of Experimental Neurosciences, I.R.C.C.S. ‘Fondazione Santa Lucia’, Rome, Italy; 3Department of Psychiatry, Vanderbilt University, Nashville, TN, USA; 4Kennedy Center for Research on Human Development, Vanderbilt University, Nashville, TN, USA; 5Department of Child Neuropsychiatry, II University of Naples, Naples, Italy; 6Department of Child Neuropsychiatry, University ‘Federico II’, Naples, Italy; 7Department of Child Neuropsychiatry, University ‘Tor Vergata’, Rome, Italy; 8Center for Autism Research and Education, Phoenix, AZ, USA; 9Southwest Autism Research and Resource Center, Phoenix, AZ, USA; 10Unit of Neurology and Clinical Neurophysiopathology, I.R.C.C.S. ‘Oasi Maria S.S.’, Troina (EN), Italy; 11Department of Psychology, University ‘La Sapienza’, Rome, Italy; 12Laboratory of Behavioral Neurobiology, Department of Experimental Neurosciences, I.R.C.C.S. ‘Fondazione Santa Lucia’, Rome, Italy and 13Department of Pediatric Research, Rikshospitalet, University of Oslo, Oslo, Norway Protein kinase C enzymes play an important role in signal transduction, regulation of gene expression and control of cell division and differentiation. The fsI and bII isoenzymes result from the alternative splicing of the PKCb gene (PRKCB1), previously found to be associated with autism.
    [Show full text]
  • PRODUCTS and SERVICES Target List
    PRODUCTS AND SERVICES Target list Kinase Products P.1-11 Kinase Products Biochemical Assays P.12 "QuickScout Screening Assist™ Kits" Kinase Protein Assay Kits P.13 "QuickScout Custom Profiling & Panel Profiling Series" Targets P.14 "QuickScout Custom Profiling Series" Preincubation Targets Cell-Based Assays P.15 NanoBRET™ TE Intracellular Kinase Cell-Based Assay Service Targets P.16 Tyrosine Kinase Ba/F3 Cell-Based Assay Service Targets P.17 Kinase HEK293 Cell-Based Assay Service ～ClariCELL™ ～ Targets P.18 Detection of Protein-Protein Interactions ～ProbeX™～ Stable Cell Lines Crystallization Services P.19 FastLane™ Structures ～Premium～ P.20-21 FastLane™ Structures ～Standard～ Kinase Products For details of products, please see "PRODUCTS AND SERVICES" on page 1～3. Tyrosine Kinases Note: Please contact us for availability or further information. Information may be changed without notice. Expression Protein Kinase Tag Carna Product Name Catalog No. Construct Sequence Accession Number Tag Location System HIS ABL(ABL1) 08-001 Full-length 2-1130 NP_005148.2 N-terminal His Insect (sf21) ABL(ABL1) BTN BTN-ABL(ABL1) 08-401-20N Full-length 2-1130 NP_005148.2 N-terminal DYKDDDDK Insect (sf21) ABL(ABL1) [E255K] HIS ABL(ABL1)[E255K] 08-094 Full-length 2-1130 NP_005148.2 N-terminal His Insect (sf21) HIS ABL(ABL1)[T315I] 08-093 Full-length 2-1130 NP_005148.2 N-terminal His Insect (sf21) ABL(ABL1) [T315I] BTN BTN-ABL(ABL1)[T315I] 08-493-20N Full-length 2-1130 NP_005148.2 N-terminal DYKDDDDK Insect (sf21) ACK(TNK2) GST ACK(TNK2) 08-196 Catalytic domain
    [Show full text]
  • Supplementary Figure S1 Tdf Binding Assay for SCH772984, Vertex 11E and GSK1120212
    Supplementary Figure S1 TdF binding assay for SCH772984, Vertex 11e and GSK1120212 ERK + 5uM GSK1120212 ERK + 5uM SCH772984 Tm = -0.15 ± 0.20 Tm = 10.3 ± 0.30 KD = NBidiNo Binding KD = 0240.24 ± 0140.14 n M Protein + 5uM Compound Protein + 5uM Compound Protein only Protein only ERK + 5uM Vertex 11e MEK + 5uM GSK1120212 Tm =68= 6.8 ± 131.3 Tm =80= 8.0 ± 0510.51 K = 5.4 ± 2.2 nM D KD = 7.1 ± 2.7 nM Protein + 5uM Compound Protein + 5uM Compound Protein only Protein only MEK + 5uM SCH772984 MEK + 5uM Vertex 11e Tm = -0.17 ± 0.14 Tm = -0.11 ± 0.13 KD = No Binding KD = No Binding Protein + 5uM Compound Protein only Protein + 5uM Compound Protein only Supplementary Figure S1 (cont.) p-ERK + 5uM GSK1120212 Tm = 0.23 ± 0.31 KD = No Binding Protein + 5uM Compound Protein only P-ERK + 5uM SCH772984 Tm = 9.8 ± 0.23 KD = 0.19 ± 0.12nM Protein + 5uM Compound Protein only p-ERK + 5uM Vertex 11e Tm =10.3 ± 1.3 KD = 0110.11 ± 0. 062nM Protein + 5uM Compound Protein only Supplementary Figure S2 Inhibition of BRAF inhibitor-induced phosphorylation of ERK by SCH772984 in HCT-116 colorectal and Calu-6 non-small cell lung cancer lines Calu-6 HCT-116 PLX4720 10uM 1uM- 10uM 1uM - 10uM 1uM- 10uM 1uM - 772984 --- + + + --- + + + 300nM pERK tERK pMEK tMEK 1 2 3 4 5 6 7 8 9 10 11 12 Supplementary Figure S3 Time course of pRSK & pERK suppression in A375 cells treated with SCH772984 or control (DMSO) A375 BRAFV600E melanoma 2hrs 6hrs 16hrs 24hrs 36hrs SCH772984 2uM _ + _ + _ + _ + _ + pRSK RSK pERK ERK pCRAF CRAF pMEK MEK pBRAF BRAF Actin Supplementary Figure S4 Supplementary
    [Show full text]
  • Supplementary Table S1. Kinase Selectivity of MPI-0479605. (A)
    A B In-house kinase profiling Invitrogen SelectScreen Profiling % % % Kinase IC50 ( M) Kinase IC50 ( M) inhibition inhibition inhibition AKT3 >5 IKK-epsilon >5 Kinase at 500 nM Kinase at 500 nM Kinase at 500 nM ALK 0.26 INSR 0.38 ABL1 7 GRK6 -7 PAK1 4 AUR-A >5 JAK1 >5 GRK2 4 HCK 7 PASK 6 AUR-B >5 JNK1 0.11 AKT1 2 HIPK2 9 PHKG1 8 AUR-C >5 MEK1 >5 AXL 6 HIPK4 -6 PRKCB1 -2 B-RAF 3.2 MST4 >5 BMX 14 IGF1R 37 PRKCE 0 CDK1 >5 NEK2 >5 BRSK1 -9 IRAK4 0 PRKCG 3 CDK2 >5 PDK1 >5 CAMK2D -1 ITK 9 PRKCI -2 CDK6 >5 PKA >5 CDC42 BPA 0 LCK 29 PRKCN 6 CHK1 >5 PKC-delta >5 CDK5/p25 -1 LIMK1 17 PRKCZ -5 CHK2 >5 PLK1 >5 CSF1R 82 MAP2K1 11 PRKG2 2 C-MET >5 PLK4 3.3 CSK 1 MAP2K6 2 PTK6 15 C-SRC >5 ROCK2 >5 CSNK1D 10 MAP3K3 17 RET 11 DYRK2 >5 RSK2 >5 CSNK1G1 -1 MAP3K5 -1 RPS6KA2 23 ERK2 3.9 STK33 1.1 CSNK2A2 33 MAP3K8 12 RPS6KA5 2 FAK1 2.7 TAK1 >5 DCAMKL2 2 MAPK1 0 SGK2 4 FER 0.59 TAO1 >5 DYRK1B 1 MAPK11 2 SNF1LK2 3 FLT3 0.080 TBK1 >5 EEF2K 2 MAPK12 5 SRPK2 -3 HGK >5 TRKB >5 EGFR 14 MAPK3 -2 STK22B 11 IKK-alpha >5 YES1 >5 EPHA1 6 MAPK9 61 STK23 -1 IKK-beta >5 EPHA4 -10 MAPKAPK2 9 STK24 -2 EPHB1 -33 MARK4 3 STK25 0 ERBB2 5 MELK 6 TEK 6 FGFR1 15 MERTK 7 TYK2 10 FGR 17 MKNK1 2 TYRO3 -2 FLT4 15 MST1R 3 ZAP70 5 FRAP1 7 NEK1 1 GRK4 3 NEK4 -6 Supplementary Table S1.
    [Show full text]
  • Gene Symbol Accession Alias/Prev Symbol Official Full Name AAK1 NM 014911.2 KIAA1048, Dkfzp686k16132 AP2 Associated Kinase 1
    Gene Symbol Accession Alias/Prev Symbol Official Full Name AAK1 NM_014911.2 KIAA1048, DKFZp686K16132 AP2 associated kinase 1 (AAK1) AATK NM_001080395.2 AATYK, AATYK1, KIAA0641, LMR1, LMTK1, p35BP apoptosis-associated tyrosine kinase (AATK) ABL1 NM_007313.2 ABL, JTK7, c-ABL, p150 v-abl Abelson murine leukemia viral oncogene homolog 1 (ABL1) ABL2 NM_007314.3 ABLL, ARG v-abl Abelson murine leukemia viral oncogene homolog 2 (arg, Abelson-related gene) (ABL2) ACVR1 NM_001105.2 ACVRLK2, SKR1, ALK2, ACVR1A activin A receptor ACVR1B NM_004302.3 ACVRLK4, ALK4, SKR2, ActRIB activin A receptor, type IB (ACVR1B) ACVR1C NM_145259.2 ACVRLK7, ALK7 activin A receptor, type IC (ACVR1C) ACVR2A NM_001616.3 ACVR2, ACTRII activin A receptor ACVR2B NM_001106.2 ActR-IIB activin A receptor ACVRL1 NM_000020.1 ACVRLK1, ORW2, HHT2, ALK1, HHT activin A receptor type II-like 1 (ACVRL1) ADCK1 NM_020421.2 FLJ39600 aarF domain containing kinase 1 (ADCK1) ADCK2 NM_052853.3 MGC20727 aarF domain containing kinase 2 (ADCK2) ADCK3 NM_020247.3 CABC1, COQ8, SCAR9 chaperone, ABC1 activity of bc1 complex like (S. pombe) (CABC1) ADCK4 NM_024876.3 aarF domain containing kinase 4 (ADCK4) ADCK5 NM_174922.3 FLJ35454 aarF domain containing kinase 5 (ADCK5) ADRBK1 NM_001619.2 GRK2, BARK1 adrenergic, beta, receptor kinase 1 (ADRBK1) ADRBK2 NM_005160.2 GRK3, BARK2 adrenergic, beta, receptor kinase 2 (ADRBK2) AKT1 NM_001014431.1 RAC, PKB, PRKBA, AKT v-akt murine thymoma viral oncogene homolog 1 (AKT1) AKT2 NM_001626.2 v-akt murine thymoma viral oncogene homolog 2 (AKT2) AKT3 NM_181690.1
    [Show full text]
  • Sensitivity and Gene Expression Profile of Fresh Human Acute
    Sensitivity and gene expression profile of fresh human acute myeloid leukemia cells exposed ex vivo to AS602868 Lars Petter Jordheim, Adriana Plesa, Michel Dreano, Emeline Cros-Perrial, Céline Keime, Stéphanie Herveau, Delphine Demangel, Julie A. Vendrell, Charles Dumontet To cite this version: Lars Petter Jordheim, Adriana Plesa, Michel Dreano, Emeline Cros-Perrial, Céline Keime, et al.. Sensitivity and gene expression profile of fresh human acute myeloid leukemia cells exposed exvivo to AS602868. Cancer Chemotherapy and Pharmacology, Springer Verlag, 2010, 68 (1), pp.97-105. 10.1007/s00280-010-1458-y. hal-00624174 HAL Id: hal-00624174 https://hal.archives-ouvertes.fr/hal-00624174 Submitted on 16 Sep 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Sensitivity and Gene Expression Profile of fresh human acute myeloid leukemia cells exposed ex vivo to AS602868 Running title: Gene expression profile of AS602868 Lars Petter Jordheim1,2,3, Adriana Plesa4, Michel Dreano5, Emeline Cros-Perrial1,2, Céline Keime3,6, Stéphanie Herveau1,2, Delphine Demangel3,
    [Show full text]
  • Comprehensive Analysis of Genes Involved in the Malignancy of Gastrointestinal Stromal Tumors
    ANTICANCER RESEARCH 30: 2705-2712 (2010) Comprehensive Analysis of Genes Involved in the Malignancy of Gastrointestinal Stromal Tumors MIYAKO TSUMURAYA1, HIROYUKI KATO1, KAZUHITO MIYACHI1, KINRO SASAKI1, MASAHIRO TSUBAKI1, KAZUMI AKIMOTO2 and MASAKATSU SUNAGAWA1 1Department of Surgical Oncology (Surgery I), and 2General Medical Institution, Dokkyo Medical University, Tochigi 321-0293, Japan Abstract. Background: During tumorigenesis of gastro- Gastrointestinal stromal tumors (GISTs) are mesenchymal intestinal stromal tumors (GISTs), the most frequent changes tumors that arise in the gastrointestinal tract, and account for are reported to be gain-of-function mutations in the C-KIT about 1% of gastrointestinal tumors (1). During tumorigenesis proto-oncogene. However, we speculated that additional of GISTs, the most frequent changes are reported to be gain- genetic alterations are required for the progression of GISTs. of-function mutations in the C-KIT proto-oncogene. These Patients and Methods: Using 15 cases diagnosed with GISTs, mutations can result in autophosphorylation, namely KIT we searched for novel indicator genes by microarray ligand-independent kinase activity (2). Approximately 95% analyses using an Oligo GEArray® PI3K-AKT Signaling of GISTs express the receptor tyrosine kinase KIT, which is Pathway Microarray Kit. In addition, we analyzed the useful for distinguishing these tumors from other sarcomas mutational status of C-KIT and the proliferation status that develop in the abdomen (3). In recent years, it has been indicated by the Ki-67 index. Results: The tumor established that 75-80% of GISTs harbor mutations in the localizations of the 15 GISTs were as follows: 8 in the KIT gene, and that the resulting KIT mutants play important stomach; 2 in the small intestine; 2 in the mesentery; 1 in roles in the development of these tumors (3).
    [Show full text]
  • Identifying Factors That Conctribute to Phenotypic Heterogeneity in Melanoma Progression
    Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2012 Identifying factors that conctribute to Phenotypic heterogeneity in melanoma progression Widmer, Daniel Simon Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-73667 Dissertation Originally published at: Widmer, Daniel Simon. Identifying factors that conctribute to Phenotypic heterogeneity in melanoma progression. 2012, University of Zurich, Faculty of Medicine. Eidgenössische Technische Hochschule Zürich Swiss Federal Institute of Technology Zurich Identifying factors that conctribute to Phenotypic heterogeneity in melanoma progression Daniel Simon Widmer 2012 Diss ETH No. 20537 DISS. ETH NO. 20537 IDENTIFYING FACTORS THAT CONTRIBUTE TO PHENOTYPIC HETEROGENEITY IN MELANOMA PROGRESSION A dissertation submitted to ETH ZURICH for the degree of Doctor of Sciences presented by Daniel Simon Widmer Master of Science UZH University of Zurich born on February 26th 1982 citizen of Gränichen AG accepted on the recommendation of Professor Sabine Werner, examinor Professor Reinhard Dummer, co-examinor Professor Michael Detmar, co-examinor 2012 Contents 1. ZUSAMMENFASSUNG...................................................................................................... 7 2. SUMMARY ................................................................................................................... 11 3. INTRODUCTION ...........................................................................................................
    [Show full text]
  • Genetic Variants of the Protein Kinase C-Β 1 Gene and Development Of
    Supplementary Online Content Ma RCW, Tam CHT, Wang Y, et al. Genetic variants of the protein kinase C-β 1 gene and development of end-stage renal disease in patients with type 2 diabetes. JAMA. 2010;304(8):881-889. eFigure. Structure of PRKCB1 gene and the location of SNPs genotyped eTable 1. Clinical characteristics and biochemical profile at baseline and allele frequencies at each polymorphic site of PRKCB1 stratified according to the progression to ESRD and CKD for the replication stage in Chinese type 2 diabetic patients eTable 2. Genotype distributions of PRKCB1 SNPs and hazard ratio of PRKCB1 polymorphisms for risk of CKD for the validation study in young onset Chinese type 2 diabetic patients eTable 3. Clinical characteristics of type 2 diabetic patients from the Shanghai cohort eTable 4. Functional annotation of the implicated genetic variants in PRKCB1 This supplementary material has been provided by the authors to give readers additional information about their work. © 2010 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/27/2021 eFigure. Structure of PRKCB1 gene and the location of SNPs genotyped. Shades of grey (white, shades of grey and black colour refer to r2 = 0, 0 < r2 < 1 and r2 = 1, respectively) and red (bright red and white refer to high and low |D’|, respectively) indicate the strength of pairwise LDs based on r2 and |D’| respectively. “†”refer to SNP show significant association to ESRD endpoint in the present study. † † † † © 2010 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/27/2021 eTable 1.
    [Show full text]
  • Supplemental Tables
    JPET #237347 (suppl) Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3Kδ Rodger A Allen, Daniel C Brookings, Mark J Powell1,2, Jean Delgado, Lindsay K Shuttleworth, Mark Merriman, Ian J Fahy1,3, Roohi Tewari, John P Silva, Louise J Healy1,4, Gareth C G Davies, Breda Twomey, Rona M Cutler, Apoorva Kotian, Andrea Crosby, Gillian McCluskey, Gillian F Watt and Andrew Payne The Journal of Pharmacology and Experimental Therapeutics Supplementary Table 1. Human primary cell systems in BioMap profile System Primary human cell systems Stimulation 3C Venular endothelial cells IL-1β, TNFα and IFNγ 4H Venular endothelial cells IL-4 and histamine LPS PBMCs + venular endothelial cells TLR4 ligand SAg PBMCs + venular endothelial cells TCR ligands (1x) BE3C Bronchial epithelial cells α-IgM and TCR ligands (0.001x) CASM3C Coronary artery smooth muscle cells IL-1β, TNFα and IFNγ HDF3CGF Dermal fibroblasts IL-1β, TNFα and IFNγ IL-1β, TNFα, IFNγ, EGF, bFGF and MyoF Lung fibroblasts PDGF-BB Venular endothelial cells + M1 TNFα and TGFβ /Mphg macrophages BT B cells + PBMCs Zymosan (TLR2 ligand) 1 JPET #237347 (suppl) Supplementary Table 2A. Off-target activity: Seletalisib at a concentration of 10 µM was assessed in binding or activity assays against a panel of 239 kinase enzymes Seletalisib % inhibition of control Kinase values CAMK1 (CaMK1) -15 CDK7/cyclin H/MNAT1 17 CDK9/cyclin T1 -24 CHUK (IKK alpha) -4 DAPK1 -13 GSG2 (Haspin) -12 IRAK1 0 LRRK2 -18 NUAK1 (ARK5) -18 PI4KA (PI4K alpha) -21 PI4KB (PI4K beta) -20 PIK3C2A (PI3K-C2
    [Show full text]